Effects of D-003, a mixture of high-molecular-weight sugar cane wax acids, on lipid peroxidation markers in older individuals: A randomized, double-blind, placebo-controlled study

Current Therapeutic Research - Clinical and Experimental

Volumn 69, Issue 1, 2008, Pages 36-48

  Pérez, Yohani ^a   Menéndez, Roberto ^a   Ferrer, José I ^b   Lopez, Ernesto ^b   Castaño, Gladys ^b   Fernández, Julio ^a   Ferreiro, Rosa M ^a   Fernández, Lilia ^a   Mendoza, Sarahí ^a   González, Rosa ^a   Mesa, Melbis ^b  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b Medical Surgical Research Center   (Cuba)

Author keywords

antioxidant compounds; D 003; elderly; lipid peroxidation; lipid lowering; sugar cane wax acids

Indexed keywords

ALKADIENE; ANTIOXIDANT; COPPER; D 003; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PLACEBO; SUPEROXIDE DISMUTASE;

ADULT; AGED; ARTICLE; BLOOD CHEMISTRY; CHOLESTEROL BLOOD LEVEL; CLINICAL EXAMINATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CUBA; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HEARTBURN; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUGARCANE;

EID: 41349112353     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.curtheres.2008.01.001     Document Type: Article

References (42)

1. World Health Organization. Fact sheet No. 317. Cardiovascular diseases (October 25, 2007). http://www.who.int/mediacentre/factsheets/fs317/en/index.html Accessed
2. Murray C., and Lopez A. Alternate projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349 (1997) 1498-1504
3. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterd lowering. JAMA 251 (1984) 365-374
4. Frick M., Elo O., Happa K., et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 317 (1987) 1237-1245
5. Randomised trial of chdesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383-1389
6. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Ned 339 (1998) 1349-1357
7. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360 (2002) 7-22
8. Shepherd J., Blauw G., Murphy M., et al., PROSPER Study Group (PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease. A randomised controlled trial. Lancet 360 (2002) 1623-1630
9. Krumholz H., Seeman T., Merrill S., et al. Lack of association between cholesterd and coronary heart disease mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA 272 (1994) 1335-1340
10. Manolio T., Pearson T., Wenger N., et al. Cholesterol and heart disease in older persons and women. Review of an NHLBI workshop. Ann Epidemiol 2 (1992) 161-176
11. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterd in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterd in Adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
12. Luscher T., and Barton M. Biology of the endothelium. Clin Cardiol 20 Suppl 2 (1997) II-3-II-10
13. Mas R. D-003: A new substance with promising lipid modifying and pleiotropic effects for atherosclerosis management. Drugs Future 29 (2004) 773-786
14. Menendez R., Mas R., Amor A., et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D003, a mixture of very long-chain saturated fatty acids. Can J Physiol Pharmacol 80 (2002) 13-21
15. Gamez R., Mendoza S., Mas R., et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res Clin Exp 61 (2000) 460-468
16. Gamez R., Mendoza S., Mas R., et al. Comparison of the chdesterol-lowering effects and toxicity of D-003 and lovastatin on normocholesterolaemic rabbits. Drugs R D 4 (2003) 219-229
17. Mendoza S., Gamez R., Mas R., and Goicochea E. Effects of D-003, a mixture of long-chain aliphatic primary acids, fluvastatin and the combined therapy of D-003 plus fluvastatin on the lipid profile of normocholesterolemic rabbits. Int J Tissue React 25 (2003) 81-89
18. Castaño G., Menéndez R., Más R., et al. Effects of D 003, a new hypocholesterolaemic and antiplatelet compound, on lipid profile and lipid peroxidation in healthy voluteers. Clin Drug Investig 23 (2003) 193-203
19. Castaño G., Mas R., Fernandez L., et al. Assessment of the effects of D-003, a new antiplatelet and hypocholesterolemic compound, in healthy volunteers: A phase I clinical study. Drugs R D 3 (2002) 337-348
20. Castaño G., Mas R., Fernandez L., et al. Effects of D-003 on the lipid profile of patients with type II hypercholesterolaemia: A phase II clinical study. Clin Drug Investig 23 (2003) 789-802
21. Menendez R., Mas R., Amor A., et al. Inhibition of cholesterol biosynthesis in cultured fibroblasts by D003, a mixture of very long chain saturated fatty acids. Pharmacol Res 44 (2001) 299-304
22. Menendez R., Mas R., Perez J., et al. Oral administration of D-003, a mixture of very long chain fatty acids, prevents casein-induced endogenous hypercholesterolemia in rabbits. Can J Physiol Pharmacol 82 (2004) 22-29
23. Goicochea E. Acute and oral subchronic toxicity of D-003 in rats. Toxicol Lett 118 (2000) 31-41
24. Gamez R., Mas R., Noa M., et al. Six-month toxicity study of oral administration of D-003 in Sprague Dawley rats. Drugs R D 3 (2002) 375-386
25. Gamez R., Mas R., Noa M., et al. Effects of chronic administration of D-003, a mixture of sugar cane wax high molecular weight acids, in beagle dogs. Drugs Exp Clin Res 30 (2004) 75-88
26. Gamez R., Gonzalez J., Rodeiro I., et al. In vivo genotoxic evaluation of D-003, a mixture of very long chain aliphatic acids. J Med Food 4 (2001) 85-91
27. Rodriguez M., Gamez R., Gonzalez J., et al. Lack of developmental toxicity of D-003: A mixture of long-chain fatty acids in rats. Food Chem Toxicol 41 (2003) 89-93
28. Schectman G., and Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med 100 (1996) 197-204
29. Ohkawa H., Ohishi N., and Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95 (1979) 351-358
30. Kleinveld H., Hak-Lemmers H., Stalenhoef A., and Demacker P. Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: Application of a short procedure for isolating low-density lipoprotein. Clin Chem 38 (1992) 2066-2072
31. Esterbauer H., Striegl H., Puhl H., and Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun 6 (1989) 67-75
32. Menendez R., Mas R., Amor A., et al. Effects of policosanol treatment on the susceptibility of low density lipoprotein (LDL) isolated from healthy volunteers to oxidative modification in vitro. Br J Clin Pharmacol 50 (2000) 255-262
33. Markwell M., Hass S., Bieber L., et al. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87 (1987) 206-210
34. Seigler L., and Wu W. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 27 (1981) 838-841
35. Friedewald W., Levy R., and Fredrickson D. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
36. Ahotupa M., Marniemi J., Lehtimaki T., et al. Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation. Clin Biochem 31 (1998) 257-261
37. Meraji S., Abuja P., Hayn M., et al. Relationship between classic risk factors, plasma antioxidants and indicators of oxidant stress in angina pectoris (AP) in Tehran. Atherosclerosis 150 (2000) 403-412
38. Khalil A., Fortin J., LeHoux J., and Fulop T. Age-related decrease of dehydroepiandrosterone concentrations in low density lipoproteins and its role in the susceptibility of low density lipoproteins to lipid peroxidation. J Lipid Res 41 (2000) 1552-1561
39. Janero D. Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med 9 (1990) 515-540
40. Young I., and McEneny J. Lipoprotein oxidation and atherosclerosis. Biol Soc Trans 29 (2001) 358-362
41. Fielding C., and Fielding P. Molecular physiology of reverse cholesterd transport. J Lipid Res 36 (1995) 211-228
42. Meyers C., and Kashyap M. Pharmacological elevation of high-density lipoprotein: Recent insights on mechanisms of action and atherosclerosis protection. Curr Opin Cardiol 19 (2004) 366-373